Merus NV
MRUS90.000USD
0.0000.00%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
6.83BValor de mercado
PerdaP/L TTM
Mais detalhes de Merus NV Empresa
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Informações de Merus NV
Código da empresaMRUS
Nome da EmpresaMerus NV
Data de listagemMay 19, 2016
CEOLundberg (Sven Ante)
Número de funcionários260
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 19
EndereçoYalelaan 62
CidadeUTRECHT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal3584 CM
Telefone310302538800
Sitehttps://merus.nl/
Código da empresaMRUS
Data de listagemMay 19, 2016
CEOLundberg (Sven Ante)
Executivos da empresa Merus NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-30297.00%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paolo Pucci
Mr. Paolo Pucci
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-30297.00%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 3 de jan
Atualizado em: sáb, 3 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Paradigm BioCapital Advisors LP
5.77%
Avoro Capital Advisors LLC
4.67%
Commodore Capital LP
4.65%
Deerfield Management Company, L.P.
4.02%
HBK Investments, L.P.
3.76%
Outro
77.14%
Investidores
Investidores
Proporção
Paradigm BioCapital Advisors LP
5.77%
Avoro Capital Advisors LLC
4.67%
Commodore Capital LP
4.65%
Deerfield Management Company, L.P.
4.02%
HBK Investments, L.P.
3.76%
Outro
77.14%
Tipos de investidores
Investidores
Proporção
Hedge Fund
39.38%
Investment Advisor/Hedge Fund
27.56%
Investment Advisor
13.49%
Research Firm
2.54%
Corporation
1.93%
Private Equity
1.78%
Venture Capital
1.47%
Pension Fund
0.56%
Bank and Trust
0.49%
Outro
10.81%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
498
69.89M
92.15%
-15.18M
2025Q3
434
77.32M
101.98%
-5.60M
2025Q2
411
75.46M
99.77%
-10.50M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Paradigm BioCapital Advisors LP
4.37M
5.77%
+91.82K
+2.14%
Sep 30, 2025
Avoro Capital Advisors LLC
3.54M
4.67%
+386.94K
+12.26%
Sep 30, 2025
Commodore Capital LP
3.52M
4.65%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
3.05M
4.02%
-337.71K
-9.98%
Sep 30, 2025
HBK Investments, L.P.
2.85M
3.76%
+2.85M
--
Sep 30, 2025
Westfield Capital Management Company, L.P.
2.13M
2.81%
+90.10K
+4.41%
Sep 30, 2025
RTW Investments L.P.
2.03M
2.67%
-1.98M
-49.38%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.94M
2.55%
-4.28M
-68.87%
Sep 30, 2025
Woodline Partners LP
1.67M
2.21%
+131.27K
+8.51%
Sep 30, 2025
Glazer Capital, LLC
1.62M
2.13%
+1.62M
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
AltShares Merger Arbitrage ETF
3.3%
NYLI Merger Arbitrage ETF
3.1%
ALPS Medical Breakthroughs ETF
2.89%
Goldman Sachs Hedge Industry VIP ETF
2.75%
ProShares Merger ETF
2.74%
First Trust IPOX Europe Equity Opportunities ETF
2.61%
Tema Oncology ETF
2.61%
Invesco Dorsey Wright Healthcare Momentum ETF
1.4%
Harbor Health Care ETF
1.29%
AltShares Event-Driven ETF
1.23%
Ver Mais
AltShares Merger Arbitrage ETF
Proporção3.3%
NYLI Merger Arbitrage ETF
Proporção3.1%
ALPS Medical Breakthroughs ETF
Proporção2.89%
Goldman Sachs Hedge Industry VIP ETF
Proporção2.75%
ProShares Merger ETF
Proporção2.74%
First Trust IPOX Europe Equity Opportunities ETF
Proporção2.61%
Tema Oncology ETF
Proporção2.61%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.4%
Harbor Health Care ETF
Proporção1.29%
AltShares Event-Driven ETF
Proporção1.23%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
